OBJECTIVE: To analyze the expression and correlation of microRNA-195 (miR-195), miR-125 and calreticulin in diffuse large B-cell lymphoma (DLBCL). METHODS: From April 2020 to April 2021, 80 DLBCL patients with complete data archived by the Pathology Department of Handan First Hospital and The Second Hospital of Hebei Medical University were selected as the study group, and 70 patients with reactive lymph node hyperplasia were selected as the control group. The expressions of miR-195 and miR-125 were detected by real-time fluorescence quantitative PCR, and the expression of calreticulin was detected by Western blot. Pearson correlation was used to analyze the correlation between miR-195, miR-125, calreticulin and DLBCL, and ROC curve was used to analyze the predictive value of miR-195, miR-125 and calreticulin for DLBCL. RESULTS: Compared with the control group, the expression of miR-195 decreased but miR-125 and calreticulin increased in the study group (P<0.001). The expression levels of miR-195, miR-125 and calreticulin were not related to sex, age, primary site and B symptoms of patients with DLBCL, but related to immunophenotype, Ann Arbor stage, lactate dehydrogenase, IPI score, nodule involvement and Ki-67 index. The expression of miR-195 decreased and the expression of miR-125 and calreticulin increased in DLBCL paitents with non-germinal center source, Ann Arbor stage III-IV, lactate dehydrogenase > 245 U/L, IPI score 3-5, nodule involvement≥2 and Ki-67 index≥75% (P<0.05). Pearson correlation analysis showed that miR-195 and miR-125 were negatively correlated (r=-0.536, P=0.001), miR-195 and calreticulin were negatively correlated (r=-0.545, P=0.001), while miR-125 and calreticulin were positively correlated (r=0.523, P=0.001). ROC curve showed that compared with the single diagnosis of miR-195, miR-125 and calreticulin, the combination of the three items had higher predictive value for DLBCL (P<0.001). CONCLUSION The expression of miR-195 decreases and the expression of miR-125 and calreticulin increase in patients with DLBCL. Along with the increase of disease stage and IPI score, the decrease of miR-195 and the increase of miR-125 and calreticulin aggravate gradually. The three items may participate in the occurrence and progress of DLBCL.
Humans ; MicroRNAs/genetics* ; Ki-67 Antigen/metabolism* ; Calreticulin/metabolism* ; Prognosis ; Lymphoma, Large B-Cell, Diffuse/genetics* ; Lactate Dehydrogenases/metabolism*

Based on network pharmacology and in vivo experiment, this study explored the therapeutic effect of Tetrastigma hemsle-yanum(SYQ) on sepsis and the underlying mechanism. The common targets of SYQ and sepsis were screened out by network pharmacology, and the "SYQ-component-target-sepsis" network was constructed. The protein-protein interaction(PPI) network was established by STRING. Gene Ontology(GO) term enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment were performed based on DAVID to predict the anti-sepsis mechanism of SYQ. The prediction results of network pharmacology were verified by animal experiment. The network pharmacology results showed that the key anti-sepsis targets of SYQ were tumor necrosis factor(TNF), interleukin(IL)-6, IL-1β, IL-10, and cysteinyl asparate specific proteinase 3(caspase-3), which were mainly involved in Toll-like receptor 4(TLR4)/myeloid differentiation factor 88(MyD88)/nuclear factor kappaB(NF-κB) signaling pathway. The results of animal experiment showed that SYQ can decrease the content of C-reactive protein(CRP), procalcitonin(PCT), lactate dehydrogenase(LDH), IL-6, TNF-α, and IL-1β, increase the content of IL-10, and down-regulate the protein levels of Bcl-2-associa-ted X(Bax)/B-cell lymphoma 2(Bcl2), cleaved caspase-3, TLR4, MyD88, and p-NF-κB p65/NF-κB p65. In summary, SYQ plays an anti-inflammatory role in the treatment of sepsis by acting on the key genes related to inflammation and apoptosis, such as TNF-α, IL-6, IL-lβ, IL-10, Bax, Bcl2, and cleaved caspase-3. The mechanism is the likelihood that it suppresses the TLR4/MyD88/NF-κB signaling pathway, which verifies relative prediction results of network pharmacology.
Animals ; Anti-Inflammatory Agents/therapeutic use* ; C-Reactive Protein ; Caspase 3/metabolism* ; Interleukin-10 ; Interleukin-6/metabolism* ; Lactate Dehydrogenases/metabolism* ; Myeloblastin/metabolism* ; Myeloid Differentiation Factor 88/metabolism* ; NF-kappa B/metabolism* ; Network Pharmacology ; Procalcitonin/therapeutic use* ; Sepsis/genetics* ; Toll-Like Receptor 4/metabolism* ; Tumor Necrosis Factor-alpha/metabolism* ; bcl-2-Associated X Protein/metabolism*

OBJECTIVETo investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma.

METHODSEighty patients with relapsed and refractory non-Hodgkin's B cell lymphoma were chosen in our hospital from January 2009 to June 2012, and randomly were divided into 2 groups including the CHOPE regimen group (40 patients) and CHOPE plus thalidomide group (40 patients); and the clinical efficacy, the levels of sVEGF and LDH before and after treatment, the survival rate and the III-IV degree toxic side-effects in these 2 groups were compared.

RESULTSThe clinical efficacy of CHOPE+thalidomide group was significant higher than that of CHOPE group alone (P < 0.05). The levels of sVEGF and LDH after treatment in the CHOPE+thalidomide group was significantly higher than that in CHOPE group alone before treatment (P < 0.05). The survival rate in CHOPE+thalidomide group was significant higher than that in CHOPE group alone (P < 0.05). The median survival time in CHOPE+thalidomide group was significant longer than that in CHOPE group alone (P < 0.05). The incidence of III-IV degree toxic side effects was not significantly different between 2 these groups (P > 0.05).

CONCLUSIONCompared with CHOPE regimen alone, CHOPE regimen combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma can efficiently delay the disease progression, reduce tumor burden level, enhance the long-term survival rate, morever did not increase the risk of toxic side effects.

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Cyclophosphamide ; therapeutic use ; Doxorubicin ; therapeutic use ; Etoposide ; therapeutic use ; Humans ; Lactate Dehydrogenases ; metabolism ; Lymphoma, B-Cell ; drug therapy ; Neoplasm Recurrence, Local ; Prednisone ; therapeutic use ; Survival Rate ; Thalidomide ; therapeutic use ; Treatment Outcome ; Vascular Endothelial Growth Factor A ; blood ; Vincristine ; therapeutic use

Poly (ADP-ribose) polymerase-1 (PARP-1) plays as a double edged sword in cerebral ischemia-reperfusion, hinging on its effect on the intracellular energy storage and injury severity, and the prognosis has relationship with intervention timing. During ischemia injury, apoptosis and oncosis are the two main cell death pathway sin the ischemic core. The participation of astrocytes in ischemia-reperfusion induced cell death has triggered more and more attention. Here, we examined the protective effects and intervention timing of the PARP-1 inhibitor PJ34, by using a mixed oxygen-glucose deprivation/reperfusion (OGDR) model of primary rat astrocytes in vitro, which could mimic the ischemia-reperfusion damage in the "ischemic core". Meanwhile, cell death pathways of various PJ34 treated astrocytes were also investigated. Our results showed that PJ34 incubation (10 μmol/L) did not affect release of lactate dehydrogenase (LDH) from astrocytes and cell viability or survival 1 h after OGDR. Interestingly, after 3 or 5 h OGDR, PJ34 significantly reduced LDH release and percentage of PI-positive cells and increased cell viability, and simultaneously increased the caspase-dependent apoptotic rate. The intervention timing study demonstrated that an earlier and longer PJ34 intervention during reperfusion was associated with more apparent protective effects. In conclusion, earlier and longer PJ34 intervention provides remarkable protective effects for astrocytes in the "ischaemic core" mainly by reducing oncosis of the astrocytes, especially following serious OGDR damage.
Animals ; Apoptosis ; Astrocytes ; cytology ; drug effects ; Cell Survival ; Cells, Cultured ; Glucose ; deficiency ; Humans ; Lactate Dehydrogenases ; metabolism ; Male ; Models, Biological ; Oxygen ; metabolism ; Phenanthrenes ; pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors ; pharmacology ; Rats ; Rats, Sprague-Dawley ; Signal Transduction ; drug effects

OBJECTIVETo investigate the clinicopathologic features, immunophenotype, diagnosis and differential diagnosis, and prognostic factors of testicular diffuse large B-cell lymphoma (DLBCL).

METHODSThe clinical and pathologic profiles of 58 cases of testicular DLBCL were investigated.Immunohistochemical stainings and EBER1/2 in situ hybridization were performed on formalin fixed tissues.

RESULTSThe average age of the patients was 62.1 years, and the median age was 65 years. The course of disease was short in most of the cases. Clinical stages at diagnosis were mainly stage I or II (87.9%, 51/58). Forty eight patients (82.8%) had unilateral testis involvement. Inguinal lymphadenopathy was observed in 12 (20.7%) patients and the other organs were seldom involved. Morphologically, centroblast-like neoplastic cells infiltrated interstitial tissue of testis diffusely and invaded into seminiferous tubules. Tunica albuginea and vessels were involved in 14 (24.1%) and 10 (17.2%) patients, respectively. Immunophenotype analysis showed predominant non-GCB type of DLBCL (48/58, 82.8%) by Hans classification. No EBV infection was detected. Follow-up data were available in 48 (82.8%) patients. Twenty eight patients (58.3%) died of the disease. One-year, 3-year, and 5-year overall survivals were 55.7%, 31.6% and 27.6%, respectively. Age (older than 60 years), B-symptoms, high serum level of LDH, advanced Ann Arbor stage as well as lack of combination of therapy were associated with a poor prognosis.

CONCLUSIONSThis large series of testicular DLBCL mainly present with local disease at diagnosis. Most cases show non-GCB immunophenotype. Despite early clinical stage at presentation, the prognosis is poor. Combined chemotherapy postoperation may prolong survival of the patients.

Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Child ; Cyclophosphamide ; therapeutic use ; Doxorubicin ; therapeutic use ; Follow-Up Studies ; Humans ; Immunophenotyping ; Interferon Regulatory Factors ; metabolism ; Lactate Dehydrogenases ; metabolism ; Lymphatic Metastasis ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; immunology ; pathology ; surgery ; Male ; Middle Aged ; Neoplasm Staging ; Neprilysin ; metabolism ; Orchiectomy ; Prednisone ; therapeutic use ; Proto-Oncogene Proteins c-bcl-6 ; metabolism ; Survival Rate ; Testicular Neoplasms ; drug therapy ; immunology ; pathology ; surgery ; Vincristine ; therapeutic use ; Young Adult

OBJECTIVETo study the expression of CD40 in diffuse large B-cell lymphoma (DLBCL) and its relationship with various clinical parameters, pathologic findings and prognostic data.

METHODSThe clinical information of 87 patients with DLBCL diagnosed in Jilin Province Cancer Hospital during the period from January, 2008 to october, 2012 was retrospectively reviewed. Immunohistochemical study using SP technique for CD40 was carried out. The correlation between clinicopathologic findings, CD40 expression and survival data was analyzed using statistical software.

RESULTSCases of CD40-positive DLBCL were characterized by lower age group, early clinical stage, less extranodal involvement, lower IPI index and lower ECOG score. However, there was no significant correlation between gender of patients and site of involvement (P = 0.141 and 0.729). The overall survival of patients with CD40-positive DLBCL was significantly higher than that in patients with CD40-negative DLBCL. One-way analysis of variance showed that the prognosis of DLBCL was closely associated with CD40 expression, age of patients, ECOG score, IPI index, extranodal involvement and LDH level (P < 0.05, respectively). Stratified analysis showed that CD40-positive DLBCL carried a better prognosis, irrespective of other immunophenotyping results. COX model multivariate analysis showed that the expression of CD40 closely correlated with other immunophenotyping results, ECOG score, clinical staging, treatment regimen and prognosis (P < 0.05).

CONCLUSIONThe expression of CD40 is a favorable prognostic indicator in patients with DLCBL.

Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; CD40 Antigens ; metabolism ; Cyclophosphamide ; therapeutic use ; Doxorubicin ; therapeutic use ; Female ; Follow-Up Studies ; Humans ; Immunophenotyping ; Lactate Dehydrogenases ; metabolism ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; metabolism ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prednisone ; therapeutic use ; Retrospective Studies ; Survival Rate ; Vincristine ; therapeutic use

OBJECTIVETo compare the toxic effects of three different particles on vascular endothelial cells, and to investigate the influences of particle composition and sizes on the cardiovascular toxic effects.

METHODSNano-SiO2 particles, nano-TiO2 particles, and standard quartz particles were selected as the test substances, and the nano-TiO2 particles and standard quartz particles were used as composition controls and size controls, respectively. The human umbilical vein endothelial cells were exposed to different doses (5.0, 10.0, 20.0, 40.0 µg/ml) of the three particles as well as particle-free DMEM medium (0 µg/ml dust) for 24 h. Then, the culture supernatants were collected, and the activities of lactic dehydrogenase (LDH) and total superoxide dismutase (SOD) as well as the releases of NO, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were measured.

RESULTSCompared with those of 0 µg/ml dose group, the LDH activities of all nano-SiO2 groups, 10.0, 20.0, and 40.0 µg/ml nano-TiO2 groups, and 10.0, 20.0, and 40.0 µg/ml standard quartz groups were significantly increased (P < 0.01); the SOD activities of 5.0, 10.0, and 20.0 µg/ml nano-SiO2 groups, 40.0 µg/ml nano-TiO2 group, and 20.0 and 40.0 µg/ml standard quartz groups were significantly increased (P < 0.05), but that of the 40.0 µg/ml nano-SiO2 group was significantly decreased (P < 0.01); the TNF-α releases of 10.0, 20.0, and 40.0 µg/ml nano-SiO2 groups, all nano-TiO2 groups, and 40.0 µg/ml standard quartz group were significantly increased (P < 0.01); the IL-6 releases of 10.0, 20.0, and 40.0 µg/ml nano-SiO2 groups, 20.0 and 40.0 µg/ml nano-TiO2 groups, and 40 µg/ml standard quartz group were significantly increased (P < 0.01). When the dust doses were 5.0, 10.0, 20.0, and 40.0 µg/ml, the LDH activities of nano-SiO2 groups were significantly higher than those of standard quartz groups (P < 0.05); when the dust doses were 10.0, 20.0, and 40.0 µg/ml, the LDH activities of nano-TiO2 groups were significantly lower than those of standard quartz groups (P < 0.05). When the dust doses were 5.0, 10.0, 20.0, and 40.0 µg/ml, the SOD activities of nano-SiO2 groups were significantly higher than those of standard quartz groups (P < 0.01); when the dust dose was 20 µg/ml, the SOD activity of nano-TiO2 group was significantly higher than that of standard quartz group (P < 0.01). When the dust doses were 5.0, 10.0, 20.0, and 40.0 µg/ml, the TNF-α releases of nano-SiO2 groups were significantly higher than those of standard quartz groups (P < 0.01); when the dust doses were 5.0 and 10.0 µg/ml, the TNF-α releases of nano-TiO2 groups were significantly higher than those of standard quartz groups (P < 0.01). When the dust doses were 5.0, 10.0, 20.0, and 40.0 µg/ml, the IL-6 releases of nano-SiO2 groups were significantly higher than those of standard quartz groups (P < 0.05); when the dust doses were 20 and 40 µg/ml, the IL-6 releases of nano-TiO2 groups were significantly higher than those of standard quartz groups (P < 0.05).

CONCLUSIONAll the three particles are able to exert certain toxic effects on vascular endothelial cells. Nano-SiO2 particles have the most toxic effects, and nano-TiO2 particles and standard quartz particles show uncertain effects. The toxicity of particles is linked to their composition and sizes.

Cells, Cultured ; Endothelial Cells ; pathology ; Human Umbilical Vein Endothelial Cells ; cytology ; Humans ; Interleukin-6 ; metabolism ; Lactate Dehydrogenases ; metabolism ; Nanoparticles ; toxicity ; Nitric Oxide ; metabolism ; Quartz ; toxicity ; Silicon Dioxide ; toxicity ; Superoxide Dismutase ; metabolism ; Titanium ; toxicity ; Tumor Necrosis Factor-alpha ; metabolism

OBJECTIVETo investigate the mechanism of lemon peel essential oil (LPE) on the cariogenicity of Streptococcus sobrinus (Ss).

METHODSLPE was extracted by the authors, and the minimum inhibition concentration (MIC) was measured by disc diffusion method. The LPE was used as the experimental group with concentrations ranging from 2.250 g/L to 0.281 g/L prepared with trypticase peptone yeast (TPY) culture medium, and TPY culture medium was used as the control group. Ss at the concentration of 10(8) CFU/ml was added to each group, and cultured for 6, 18, 24, 48 hours. Neson-Somogyi method was used to measure the content of reducing sugar, and glucosyltransferase (GTF) activity. The activity of lactate dehydrogenase (LDH) was measured by lactic acid and pyruvic acid continuous monitoring method. The content of water insoluble glucan (WIG) was measured by anthrone method, and the pH value of the culture solution was detected. The value of pH before the experiment and the time difference was alculated as ΔpH.

RESULTSAt the same time point, the activity of GTF and LDH and the concentration of WIG and the value ΔpH decreased gradually with the increase of concentration of LPE. There were significant differences between each experimental group and control group (P < 0.01). The control group had the maximum value, GTF: (6.71 ± 0.61) mIU, LDH: (135.8 ± 1.7) U/L, WIG: (47.15 ± 5.12) mg/L, ΔpH: (2.67 ± 0.01). The highest drug concentration group had the minimum value: GTF: (0.39 ± 0.07) mIU, LDH: (95.0 ± 5.4) U/L, WIG: (2.44 ± 0.38) mg/L, ΔpH: (0.61 ± 0.01).

CONCLUSIONSThe LPE below the MIC could still inhibit the GTF, LDH activity and lead to the decrease of WIG and the acid production.

Dose-Response Relationship, Drug ; Glucans ; biosynthesis ; Glucosyltransferases ; antagonists & inhibitors ; metabolism ; Lactate Dehydrogenases ; antagonists & inhibitors ; metabolism ; Microbial Sensitivity Tests ; Oils, Volatile ; pharmacology ; Plant Oils ; pharmacology ; Streptococcus sobrinus ; drug effects ; metabolism

OBJECTIVETo study the protective effect and mechanism of salvianolic acid B (Sal B) on glutamate-induced excito-toxicity.

METHODGlutamate-induced PC12 cell injury model was established to detect the cell survival rate by MTT, the leakage rate of lactic dehydrogenases using LDH, and the cell apoptosis by using AO/EB double staining for fluorescence microscope and PI single staining flow cytometry which was also used to detect the content of intracellular reactive oxygen species. The expression of Caspase-3 protein was also detected by the Western blotting method.

RESULTSal B is proved to inhibit glutamate-induced PC12 cells from injury and prevent them from releasing LDH within the range from 50 micromol x L(-1) to 200 micromol x L(-1). Meanwhile, Sal B has an effect on significantly reducing the expression of inhibit glutamate-induced active Caspase-3 protein, inhibiting accumulated glutamate-induced ROS and decreasing PC12 cell apoptosis rate within the range from 50 micromol x L(-1) to 200 micromol x L(-1).

CONCLUSIONThe study proves that Sal B prevented against glutamate-induced cell injury via inhibiting ROS formation and Caspase-3 pathway-dependent apoptosis in PC12 cells.

Action Potentials ; drug effects ; Animals ; Apoptosis ; drug effects ; Benzofurans ; pharmacology ; Caspase 3 ; metabolism ; Cell Proliferation ; drug effects ; Drugs, Chinese Herbal ; pharmacology ; Excitatory Amino Acid Antagonists ; pharmacology ; Glutamic Acid ; adverse effects ; Lactate Dehydrogenases ; metabolism ; PC12 Cells ; Pheochromocytoma ; metabolism ; Rats ; Reactive Oxygen Species ; metabolism

OBJECTIVETo study the cytotoxicity induced by chrysotile asbestos (CA), rock wool (RW) and wollastonite (WS).

METHODSV79 cells were divided into 4 groups. i.e. CA group, WS group, RW group and control group (200 microl PBS). The exposure concentration of dusts was 100 mg/L, The cell viability was detected by MTT and lactate dehydrogenase (LDH) activity assays. The technique of scanning electron microscopy was used to examine the change of V79 cells.

RESULTSSiO2 was main constituent for 3 kinds of dusts. In MTT assay, the cell viability of RW and WS groups was 64.8% and 65.7%, respectively, which were significantly higher than that (54.5%) of CA group (P < 0.01). In LDH assay, the LDH activity of RW and WS groups [(15.7 +/- 50.9), (12.3 +/- 3.7) U/L, respectively] was significantly lower than that [(20.2 +/- 0.9) U/L] of CA group (P < 0.05). In scanning electron microscopy examination, it was found that the two ends of V79 cells in CA group contained a great deal of fibers remaining bodies, but the V79 cell appearance in RW and WS groups was normal.

CONCLUSIONThe cytotoxicity induced by RW and WS is significantly lower than that induced by CA for V79 cell.

Animals ; Asbestos, Serpentine ; toxicity ; Calcium Compounds ; toxicity ; Cell Line ; drug effects ; Cricetinae ; Cytotoxins ; toxicity ; Lactate Dehydrogenases ; metabolism ; Mineral Fibers ; toxicity ; Silicates ; toxicity